Dr. Eric Jonasch
The University of Texas MD Anderson Cancer Center
Department of Genitourinary Medical Oncology
I am a medical oncologist focused on the treatment of VHL related disease, including sporadic renal cell carcinoma and hereditary von Hippel Lindau disease.
My research focuses on three major themes:
Determinants of Response and Resistance to Targeted Therapy. The cornerstone of our work is the tissue-rich clinical trial. Laboratory techniques include protein tissue microarrays, reverse phase protein microarrays, gene expression microarrays and serum and plasma based assays. We also use cell-line based xenograft models to test novel ways to overcome resistance.
Discovering and Characterizing Novel VHL Binding Proteins. We have discovered a number of novel VHL binding partners, and are defining their mechanistic significance. Techniques used in this work include tissue culture, GFP trap and coimmunoprecipitation assays, stable isotope labeling by amino acids in cell culture (SILAC) in conjunction with mass spectrometric analyses, ubiquitination assays, Western blotting, plasmid generation and site directed mutagenesis.
Modulating Proteostasis of VHL Protein in VHL Related Disease Point mutated VHL is thermodynamically unstable and may be targeted by the ubiquitin proteasome system. As part of a Nanomedicine Roadmap Initiative grant, we are devising novel ways to stabilize and refunctionalize mutated VHL. We use similar techniques to above, and perform and assess readouts from high-throughput screening assays.
Tutorials could include learning how to use the Vectra Multispectral Imaging System to analyze human tissue samples, how to perform GFP trap assays in conjunction with SILAC, how to set up a high throughput cell-based screen, and how to set up tissue endpoints in clinical trials.
Office: MDA CPB7.3506 (Unit 1374)
Title: Associate Professor
M.D. - McGill University - 1992